We report a 5-year-old boy with juvenile myelomonocytic leukemia (JMML) which relapsed after an allogeneic bone marrow transplant who was successfully treated with interferon-␣ (IFN-␣). One year after starting the therapy, he remains clinically well and in complete remission while continuing treatment with IFN-␣ and bestatin. Although the precise mechanism by which remission was induced is uncertain, a GVL effect combined with a direct antileukemia effect of IFN-␣ may be responsible. Further assessment of the role of IFN-␣ in relapsed JMLL patients is warranted. Bone Marrow Transplantation (2000) 26, 681-683.
Juvenile myelomonocytic leukemia (JMML) is a rare myeloproliferative syndrome which occurs during early childhood. It is characterized by peripheral blood monocytosis and bone marrow dysplasia, often associated with monosomy 7. It is usually associated with increased levels of fetal hemoglobin, hypersensitivity of peripheral blood hematopoietic progenitors to granulocyte-macrophage colony-stimulating factor, and hepatosplenomegaly. In general, it is a disease with a variable course; in a significant proportion of patients the disease progresses rapidly, and others show an indolent course. Treatment modalities include non-intensive chemotherapy, intensive induction therapy, allogeneic stem-cell transplantation (allo-SCT), and investigational agents such as isotretinoin and cytokines such as interferon-␣ (IFN-␣). Although BMT is the approach most likely to produce long-term disease-free survival, relapse after BMT remains a significant issue.
IFN-␣ has been reported to be effective in chronic myeloid leukemia (CML) patients who relapse after allo-SCT.
1,2 The activity of IFN-␣ in an SCT setting combines antiproliferative and immunomodulating effects. 3 Enhancement of the graft-versus-host-disease (GVHD) or graft-ver- sus-leukemia (GVL) effect was considered to be responsible for this immunomodulation. Although there are some reports on the treatment of JMML with IFN-␣ without SCT, 4-9 attainment of remission of JMML with IFN-␣ following relapse after an allo-SCT has not been reported. We report a patient with relapsed JMML after BMT who achieved a sustained and complete remission with IFN-␣.
Case report
A 5-year-old boy was admitted because of fever in May 1998. There was cervical lymphoadenopathy, and mild petechiae were found. His spleen was palpable 5 cm, and liver 3 cm below the costal margins. The hemoglobin was 93 g/l, platelet count 28 × 10 9 /l, and white blood cell count 14 × 10 9 /l (32.5% neutrophils, 0.5% basophils, 18% lymphocytes, 41.5% monocytes, and 7.5% blasts). Bone marrow showed normal cellularity with 14% promyelocytes and 21% blasts. Fetal hemoglobin was 38%. Chromosome analysis showed no abnormalities. Based on these findings, the patient was diagnosed with JMML. Following three courses of combined chemotherapy (cytarabine, etoposide with or without daunorubicin), the hepatosplenomegaly and thrombocytopenia improved. Bone marrow examination showed marked reduction of blasts (0.5%) with persistent dysplasia. In August 1998, allo-BMT was performed from an HLA-identical sister. The conditioning regimen consisted of thiotepa (600 mg/m 2 ), cyclophosphamide (120 mg/kg), and total body irradiation (12 Gy in four fractions). A short course of methotrexate was administered for GVHD prophylaxis. Engraftment was uneventful with neutrophils above Ͼ0.5 × 10 9 /l on day 24. He developed grade I acute cutaneous GVHD on day 18, for which cyclosporin A and methylprednisolone were administered. However, he developed grade II cutaneous GVHD on day 37, and cyclosporin A was replaced by tacrolimus. Following an improvement of GVHD, methylprednisolone was tapered and discontinued in January 1999, and tacrolimus was tapered from February 1999.
In March 1999, pancytopenia progressed. Laboratory blood tests showed hemoglobin 85 g/l, platelets 69 × 10 9 /l, and a white blood count of 2.8 × 10 9 /l with 5% blasts. BM examination revealed a hematological relapse with 12% blasts. Chromosome analysis showed monosomy 7 with a t(12;14)(q13;q24) in 16 of 20 metaphases, which had not been found at initial presentation, and fluorescence in situ hybridization (FISH) analysis of sex chromosomes showed that 41.3% of the cells were recipient type (Table 1) . On the same day as the diagnosis of relapse, tacrolimus was discontinued. One week after withdrawal of tacrolimus, thrombocytopenia (45 × 10 9 /l) and leukocytopenia (22 × 10 9 /l) persisted. As a consequence, immunotherapy with subcutaneous injection of natural IFN-␣ at 1.5 million units per day was initiated. Two weeks after the initiation of IFN-␣, at which time thrombocytopenia (20 × 10 9 /l) and leukocytopenia (9 × 10 9 /l) continued together with mixed chimerism of bone marrow (Table 1) , the patient developed grade I acute cutaneous GVHD. This persisted for 1 month and resolved spontaneously without immunosuppressive agents. Two months after starting IFN-␣, peripheral blood findings showed a platelet count of 171 × 10 9 /l and white blood cell count of 37 × 10 9 /l without blasts, while a bone marrow study confirmed hematological and cytogenetic remission with complete chimerism (Table 1) . Since the spontaneous resolution of cutaneous GVHD, he received 3 million units of IFN-␣ three to five times per week combined with 15 mg of oral bestatin daily to enhance the GVL effect. One year after starting IFN-␣ therapy, the boy remains clinically well and in complete remission, while continuing IFN-␣ and bestatin. During IFN-␣ therapy, the serum concentration of soluble interleukin-2 receptor (sIL-2R) remained elevated ( Table 1) .
Discussion
Although JMML is curable only with SCT, relapse after SCT remains a significant issue. We observed a complete hematological and cytogenetic remission with IFN-␣ therapy in a patient with hematological relapse of JMML after an allo-BMT.
In general, in the event of relapse after allo-SCT, discontinuation of immunosuppressive drugs is often performed to induce a GVL effect, sometimes combined with donor lymphocyte infusion (DLI). However, literature on the treatment of relapsed JMML after SCT is scarce. Lutz and colleagues 10 reported a case of complete remission after discontinuation of cyclosporin A and another of a transient partial response after DLI. Other studies have also described remission after discontinuation of cyclosporin A in cases of JMML relapsing after SCT. [11] [12] [13] These patients developed acute GVHD after cessation of cyclosporin A, suggesting that cyclosporin A suppressed GVL as well as GVHD effects in these patients. However, in our patient, cessation of tacrolimus induced neither GVHD nor improvement of hematological findings up to 3 weeks after discontinuation, indicating that GVL was not being prevented by tacrolimus.
IFN-␣ has been used as initial therapy in a small number of patients with JMML; responses were occasionally observed, though not as consistently as in CML. [4] [5] [6] [7] [8] [9] Aricò et al 7 reported that five of seven patients with JMML, who received IFN-␣ with or without chemotherapy, remained alive. However, the patients in their study did not attain complete remission, but rather had stable disease. In two other studies, 4, 6 no complete response was observed and a transient response to IFN-␣ was only observed in a single patient. Thus, the activity of IFN-␣ against JMML is limited.
The mechanism by which IFN-␣ induced complete remission in our patient is uncertain. However, it is probable that it involved enhancement of allo-reactivity of donor origin cytotoxic T cells and, to a lesser extent, a direct antileukemia effect. Indeed, after starting IFN-␣ therapy, disappearance of the leukemia cells was concomitant with the development of acute GVHD and was accompanied by an elevation of serum sIL-2R level. Serum sIL-2R level has been reported as reflecting the severity of acute GVHD, 14, 15 and presumably the extent of the GVL effect. Analogous findings have been observed in patients with CML where IFN-␣, alone or combined with DLI, induced complete responses in a substantial number of patients who had relapsed after SCT. 1, 2 DLI is another modality for the treatment of relapse after allo-SCT, and is especially effective for CML. However, there are no reports describing achievement of complete remission using DLI in relapsed JMML after SCT. Thus, the role of DLI in JMML is uncertain. DLI occasionally induces uncontrollable GVHD leading to death, while the effect of IFN-␣ is reversible when administration is stopped. Thus, we preferred IFN-␣ administration to DLI.
We treated the patient with bestatin combined with IFN-␣. Bestatin, an inhibitor of aminopeptidase N, is reported to induce apoptosis of leukemia cells by enhancement of caspase-3, 16 to enhance cytotoxic activity of lymphocytes, 17 and to activate monocytes. 18 In the setting of BMT, administration of bestatin after transplantation promoted an increase of NK cells, B cells and CD4/CD8 ratio, 19 and decreased the rate of leukemia relapse via a GVL effect. 20, 21 The addition of bestatin might have contributed to the maintenance of a GVL reaction in our patient.
In conclusion, we successfully treated a patient with JMML who relapsed after allo-BMT using IFN-␣, raising the possibility of a promising therapy for such patients. Further assessment is therefore warranted on the use of IFN-␣ therapy in relapsed JMLL patients.
